icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
yzMpbL4nKDVCP1w0